Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boehringer ingelheim animal health belgium sa-nv - fipronil 67,6 mg/1 ml; permethrin 504,8 mg/1 ml - spot-on solution - 67,6 mg/ml - 504,8 mg/ml - fipronil 67.6 mg/ml; permethrin 504.8 mg/ml - fipronil, combinations - dog

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

ck polymers - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

proficient rx lp - dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - dipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement. hypersensitivity to dipyridamole and any of the other components.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - metronidazole gel, 1% is nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. metronidazole gel is contraindicated in patients with a history of hypersensitivity to metronidazole or to any other ingredient in the formulation. risk summary available data have not established an association between metronidazole use during pregnancy and major birth defects, miscarriage or other adverse maternal or fetal outcomes. no fetotoxicity was observed after oral administration of metronidazole in pregnant rats or mice. the available data do not allow the calculation of relevant comparisons between the systemic exposures of metronidazole observed in animal studies to the systemic exposures that would be expected in humans after topical use of metronidazole gel. the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary it is not known whether metronidazole is present in human milk after topical administration. published literature reports the presence of metronidazole in human milk after oral administration. there are no data on the effects of metronidazole on milk production. because of the potential for serious adverse reactions, advise patients that breastfeeding is not recommended during treatment with metronidazole gel. safety and effectiveness of metronidazole gel have not been established in pediatric patients. sixty-six subjects aged 65 years and older were treated with metronidazole gel, 1% in the clinical study. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

aleor dermaceuticals limited - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - metronidazole gel, 1% is indicated for the topical treatment of inflammatory lesions of rosacea. metronidazole gel is contraindicated in patients with a history of hypersensitivity to metronidazole or to any other ingredient in the formulation. teratogenic effects : pregnancy category b. there are no adequate and well-controlled studies with the use of metronidazole gel in pregnant women. metronidazole crosses the placental barrier and enters the fetal circulation rapidly. no fetotoxicity was observed after oral administration of metronidazole in rats or mice at 200 and 20 times, respectively, the expected clinical dose. however, oral metronidazole has shown carcinogenic activity in rodents. because animal reproduction studies are not always predictive of human response, metronidazole gel should be used during pregnancy only if clearly needed. after oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. even though blood levels taken after topical

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

opella healthcare france sas t/a sanofi - triamcinolone acetonide - nasal spray, suspension - 55 microgram(s)/dose - corticosteroids; triamcinolone

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

opella healthcare france sas t/a sanofi - triamcinolone acetonide - nasal spray, suspension - 55 microgram(s)/dose - corticosteroids; triamcinolone

Κένυα - Αγγλικά - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - artesunate & amodiaquine tablets 25/67.5mg - tablet - artesunate 25mg & amodiaquine 67.5mg - antimalarial antiprotozoals: combinations of

Καναδάς - Αγγλικά - Health Canada

baxter corporation - dextrose - solution - 33.3g - dextrose 33.3g - caloric agents

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - mesalazine 16.67%{relative} - suppository - 16.67% w/w - active: mesalazine 16.67%{relative} excipient: hard fat